The RheumNow Week in Review - 20 October 2017 Save

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

1. Dr Munther Khamashta at #APLAR2017 lecturing on Catastrophic APS - seen in 0.8% of APS pts. https://t.co/v1rfsjvqJ9
2. Nearly half Catastrophic APS triggered by infections. Much less are surgery, SLE, stopping anticoagulants.… https://t.co/altMOsLOez
3. Infection as most common trigger led to hypothesis of molecular mimicry w/ aB2GP1. Over 85% of pts have at least 1… https://t.co/zrdv7AZBcn
4. Most common organ system involved in Catastrophic APS is abdominal/renal followed by pulmonary. #APLAR2017 https://t.co/L2XHvrv7jf
5. Deaths from catastrophic APS is down from 50% to 37% with earlier Dx and Rx. #APLAR2017 https://t.co/FWUA3vItri
6. Of the ~65% early RA pts on low dose pred (3.1mg/d) x7 yrs had more NSAIDs, DMARD, biologics, Dz activity, CRP & CCP https://t.co/dOY5kpSKwa
7. Janssen halts anti-IL6 sirukumab development citing FDA rejection and need for more clinical data. https://t.co/3SLehEbLO0
8. Pilot trial 20 pt w/ DM/PM Rx w/ IV Abatacept; half improved; Bxs showed increased Foxp3+ Tregs. https://t.co/S8sX4JO86v
9. Population survey found psoriasis/PsA in 1.4-3.3%; Nearly 1/2 not seeing MD or stopped biologic for safety/no effect https://t.co/JGHWuIUacK
10. Looking at 2 different datasets, having PsA confers a 30+% risk of Cardiovascular dz https://t.co/0OcGOUDg9T
11. Tofacitinib Scores in TNF inhibitor Resistant Psoriatic Arthritis
12. Rheumatologists are Slow to Change DMARDs 
13. High Drug Discontinuations and Nonadherence in Fibromyalgia
14. Hepatitis A Outbreak in San Diego